Peritoneal Mesothelioma Survival Rate

Peritoneal mesothelioma carries a median overall survival of roughly 17 to 21 months across large national databases, but that number conceals enormous variation depending on treatment, tumor biology, and patient characteristics. At one extreme, people with unresectable disease who receive only supportive care may survive less than a year. At the other, patients treated with aggressive surgery and heated intraperitoneal chemotherapy at specialized centers can reach five-year survival rates above 50%. Few cancers have such a wide gap between the best-case and worst-case scenarios, which makes understanding what drives the numbers far more useful than fixating on a single median figure.

Why the Survival Range Is So Wide

The single biggest factor separating long survivors from short survivors is whether a patient undergoes cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy, commonly called CRS-HIPEC. In this procedure, surgeons remove all visible tumor from the abdominal cavity and then bathe the exposed surfaces in heated chemotherapy. A multi-institutional study found that the combination of complete cytoreduction and HIPEC were independently associated with improved survival in multivariate analysis.¹ Data from a single high-volume center confirmed that CRS-HIPEC significantly improves survival over historical untreated baselines.²

A recent National Cancer Database analysis of over 3,600 patients found the overall median survival was about 18 months, but among long-term survivors, defined as those living at least five years, the median stretched to roughly 92 months. That long-term group made up about 18% of all patients and shared common traits: they were more likely to be female, younger, treated at academic centers, and to have received radical surgery plus chemotherapy.³ In short, the “average” survival figure blends together a group with dismal outcomes and a group that may live for years, making it a poor guide for any individual patient.

Completeness of Cytoreduction Is the Strongest Surgical Predictor

Surgeons grade how much visible tumor they leave behind using a completeness-of-cytoreduction score. A CC-0 means no residual disease is visible; CC-1 means residual nodules under 2.5 millimeters remain. CC-2 and CC-3 indicate progressively larger tumor left in place. The survival difference between these groups is stark. One analysis reported a median overall survival of nearly 57 months for patients achieving CC-0 or CC-1, compared with about 7 months for those left with CC-2 or CC-3 residual disease.⁴ Progression-free survival showed a similar pattern, with CC-0/1 patients staying disease-free for a median of about 16 months versus roughly 5 months for incomplete resections.

Completeness of cytoreduction has emerged as a significant independent predictor in multivariate analyses across multiple studies.⁵ This is why experienced surgeons spend hours meticulously stripping tumor from the peritoneal lining, sometimes removing portions of organs to achieve a complete resection. For the patient, the practical takeaway is direct: getting to a center that can achieve CC-0 or CC-1 matters more than almost any other decision in the treatment pathway.

How Tumor Spread Is Measured

Before and during surgery, doctors assess how extensively the tumor has spread across the peritoneum using the peritoneal cancer index, a scoring system that divides the abdomen into 13 regions and rates tumor burden in each. A multi-institutional study grouped patients into tiers by this index. Those with the lowest tumor burden (scores of 1 to 10) and no lymph node involvement or distant metastases had significantly better survival than all other groups. Patients with intermediate scores (11 to 30) fell in between, and those with the highest scores (above 30) or any lymph node or distant spread did poorly regardless of other factors.⁶

The connection between tumor burden and cytoreduction completeness is intuitive: less disease spread means a surgeon is more likely to remove everything visible. These two factors reinforce each other, which is part of why patients caught early tend to do so much better.

Histological Subtype and Its Effect on Prognosis

Peritoneal mesothelioma comes in three main tissue types. The epithelioid subtype, which accounts for the majority of cases, carries the best prognosis. Biphasic tumors contain a mix of epithelioid and sarcomatoid cells and fall in between. Pure sarcomatoid tumors are the most aggressive and rarest. Overall survival is significantly longer for epithelioid tumors than for biphasic or sarcomatoid tumors, a finding that holds regardless of when patients were diagnosed or what treatment era they belong to.⁷

Patients with sarcomatoid histology are generally excluded from CRS-HIPEC because the aggressive biology tends to overwhelm the benefits of surgery. Biphasic tumors used to be similarly excluded, but a retrospective analysis from a large international registry offered a more nuanced picture. Among patients who achieved complete cytoreduction (CC-0), five-year survival was about 65% for epithelioid cases and roughly 50% for biphasic cases. But when visible tumor remained after surgery (CC-2), patients with biphasic disease survived a median of only about four months. The conclusion: CRS-HIPEC can still help biphasic patients, but only when complete resection is achievable.⁸

Sex and Age Differences

Women with peritoneal mesothelioma consistently live longer than men, and the gap is not small. One population-based study found that women had roughly half the five-year risk of death compared with men, independent of age, diagnosis era, or histology.⁹ A separate analysis focused on sex specifically confirmed significantly improved survival in female patients and noted that older women had worse outcomes than younger women, a pattern not seen in men.¹⁰

One hypothesis involves sex hormones. Research has shown that women with epithelioid mesothelioma had significantly higher survival than men with the same subtype, and that their overall median survival exceeded 60 months compared with 43 months for men. Intriguingly, the female survival advantage narrowed after menopause when benign cystic mesothelioma cases were excluded, suggesting hormonal factors may play a protective role.¹¹ National-level data have confirmed that advanced age, male sex, lack of insurance, and aggressive histological subtypes all independently predict worse outcomes.¹²

What Drugs Are Used During HIPEC

The chemotherapy agents heated and circulated through the abdominal cavity during HIPEC have been debated for years. A 2022 international consensus from the Peritoneal Surface Oncology Group International favored a two-drug approach, specifically cisplatin combined with doxorubicin, as the recommended regimen.¹³ This preference is backed by outcome data. A French registry study of 249 patients found that using two chemotherapy agents yielded better overall survival than using a single agent, with the benefit most pronounced in patients with epithelioid subtype who achieved complete cytoreduction.¹⁴ A systematic review of HIPEC protocols confirmed that the cisplatin-plus-doxorubicin combination appeared both safe and more effective than monotherapy.¹⁵

When Surgery Is Not an Option

Not everyone is a candidate for CRS-HIPEC. Patients with extensive disease that cannot be fully resected, significant medical comorbidities, or sarcomatoid histology typically receive systemic chemotherapy instead. The standard first-line regimen mirrors what is used for pleural mesothelioma: pemetrexed combined with cisplatin. A study of this combination reported a median progression-free survival of about 7 months and median overall survival of roughly 15 months, with a response rate of 38% among patients with measurable tumors.¹⁶ These numbers are substantially lower than what CRS-HIPEC achieves, which underscores why surgical candidacy is pursued so aggressively when feasible.

Immunotherapy Enters the Picture

Immune checkpoint inhibitors have transformed treatment for several cancers, and early data suggest they may have a role in peritoneal mesothelioma, though the evidence remains limited. A study of 29 patients treated with checkpoint inhibitors, most with the combination of nivolumab and ipilimumab, found an overall response rate of about 19%. No significant difference in response was seen between dual-agent and single-agent immunotherapy.¹⁷ Case reports have described striking individual responses, including one patient with unresectable disease who experienced a major, sustained 12-month response to nivolumab plus ipilimumab, with molecular features including high PD-L1 expression and loss of BAP1 protein expression.¹⁸

These results are early and based on small numbers, so immunotherapy is not yet a standard treatment. But for patients whose tumors are not surgically resectable and who have progressed on chemotherapy, checkpoint inhibitors represent one of the few active areas of clinical investigation.

The BAP1 Gene and Long-Term Survival

A molecular feature that has attracted considerable attention is the BAP1 tumor-suppressor gene. Alterations in BAP1, through mutation, copy-number loss, or loss of protein expression, occur in more than 70% of malignant peritoneal mesotheliomas.¹⁹ Counterintuitively, patients whose tumors show BAP1 mutations or protein loss tend to live longer, not shorter. That same study found better overall survival in patients with BAP1 alterations, independent of histological subtype, age, and sex.

The link is even more dramatic in patients carrying germline (inherited) BAP1 mutations. An analysis of pooled data found that mesothelioma patients with germline BAP1 mutations who developed peritoneal disease had a median survival of about 10 years.²⁰ These are people with an inherited cancer-predisposition syndrome who paradoxically develop a more indolent form of the disease. Understanding BAP1 status is increasingly viewed as a useful prognostic tool, and it may eventually help guide treatment decisions, though its direct therapeutic implications are still being worked out.

How Peritoneal Compares with Pleural Mesothelioma

Most people associate mesothelioma with the lungs, but the peritoneal form, which lines the abdomen, is a distinct disease with a notably better prognosis. A comparative study of both subtypes found that peritoneal mesothelioma had a median survival of about 21 months versus roughly 10 months for pleural mesothelioma, and that the peritoneal form remained associated with improved survival after adjusting for confounders.²¹ The difference reflects both the biology of the two diseases and the availability of CRS-HIPEC for peritoneal tumors, a treatment approach without a direct equivalent in pleural disease. Survival modeling for pleural mesothelioma illustrates the contrast: among men aged 50 to 79 with localized pleural disease, only about 7% survived five years.²²

Delayed Diagnosis Is Common

Part of what makes peritoneal mesothelioma challenging is that its early symptoms, abdominal bloating, vague pain, changes in bowel habits, and fluid buildup, overlap with dozens of common conditions. The average time from symptom onset to formal diagnosis has been reported at four to six months, though it can stretch much longer.²³ During that window, the tumor may progress from a stage where complete cytoreduction is straightforward to one where it is difficult or impossible. Given how strongly completeness of resection predicts survival, any delay has real consequences.

Blood Markers That May Help Predict Outcomes

Researchers have been looking for simple blood tests that might indicate how aggressive a patient’s disease is. The neutrophil-to-lymphocyte ratio, a cheap and widely available measure of systemic inflammation, has emerged as an independent predictor of survival. Two separate studies found that a high ratio before or after treatment was associated with worse outcomes.²⁴ One of those studies, specifically evaluating patients who underwent CRS-HIPEC, confirmed that post-operative values of this ratio, along with the Ki-67 proliferation marker and histological type, were significantly associated with survival in multivariate analysis.²⁵ Low albumin levels also predicted worse outcomes. These markers are not used to make treatment decisions on their own, but they add context to the overall picture.

Repeat Surgery for Recurrence

Peritoneal mesothelioma frequently recurs even after successful CRS-HIPEC. When it does, some patients are candidates for a second round of surgery and heated chemotherapy. One study found that patients who underwent a repeat procedure had a median overall survival of 80 months, compared with about 27 months for those who had a single operation.²⁶ A second study found a similar trend, with 62 months for repeat operations versus 22 months for a single surgery, though in that case the difference did not reach statistical significance, likely due to the small sample size.²⁷ Selection bias is real here: patients strong enough to tolerate a second major surgery are inherently healthier. Still, the data suggest that re-operation should be considered rather than dismissed when disease comes back in a manageable form.

PIPAC for Patients Who Cannot Have Open Surgery

A newer approach called pressurized intraperitoneal aerosol chemotherapy, or PIPAC, delivers chemotherapy as a fine mist during a minimally invasive laparoscopic procedure. It is intended for patients whose disease is too widespread for standard cytoreduction. An early study reported that PIPAC induced significant tumor regression in over half of patients, with a cumulative effect seen after repeated treatments, and a median overall survival of about 27 months from first application.²⁸

In some cases, repeated PIPAC sessions can shrink disease enough to make standard CRS-HIPEC feasible. A cohort study found that patients who were initially deemed unresectable but went on to have surgical resection after PIPAC had significantly better progression-free survival than those who remained inoperable, with a median of about 34 months versus 7 months.²⁹ One remarkable case report documented a patient who received 24 PIPAC procedures over seven years for unresectable disease, achieving prolonged periods of stable disease with no major side effects, after having refused standard systemic chemotherapy.³⁰ PIPAC remains investigational for mesothelioma, but it is expanding the options for patients previously considered untreatable.

Where You Get Treated Matters

This is a rare cancer, and the institutions that treat it range from large academic centers with dedicated peritoneal surface malignancy programs to community hospitals that may see only a handful of cases per year. The difference in outcomes is measurable. A study comparing academic and community facilities found unadjusted five-year survival rates of about 30% at academic centers versus 18% at community hospitals. Even after controlling for patient and tumor characteristics, treatment at a community facility was independently associated with a higher risk of death.³¹ The National Cancer Database analysis of long-term survivors reinforced this finding, showing that treatment at academic or research centers and high-volume institutions was significantly more common among those who survived beyond five years.³² For a surgery as complex as CRS-HIPEC, institutional experience in patient selection, operative technique, and post-operative care all contribute to better results. If you or someone you know faces this diagnosis, seeking a referral to a specialized center is one of the most impactful decisions available.